IRWD Quote, Financials, Valuation and Earnings

Akebia Therapeutics, Inc. has a net margin of 32.84% compared to Ironwood Pharmaceuticals, Inc.'s net margin of 0.92%. Ironwood Pharmaceuticals, Inc.'s return on equity of -- beat Akebia Therapeutics, Inc.'s return on equity of --.

Ironwood Pharmaceuticals, Inc. has a consensus price target of $3.17, signalling downside risk potential of -22.39%. On the other hand Akebia Therapeutics, Inc. has an analysts' consensus of $5.40 which suggests that it could grow by 252.94%. Given that Akebia Therapeutics, Inc. has higher upside potential than Ironwood Pharmaceuticals, Inc., analysts believe Akebia Therapeutics, Inc. is more attractive than Ironwood Pharmaceuticals, Inc..

Ironwood Pharmaceuticals, Inc. has a beta of 0.185, which suggesting that the stock is 81.483% less volatile than S&P 500. In comparison Akebia Therapeutics, Inc. has a beta of 0.354, suggesting its less volatile than the S&P 500 by 64.559%.

Ironwood Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akebia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ironwood Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Akebia Therapeutics, Inc. pays out -- of its earnings as a dividend.

Ironwood Pharmaceuticals, Inc. quarterly revenues are $122.1M, which are larger than Akebia Therapeutics, Inc. quarterly revenues of $58.8M. Ironwood Pharmaceuticals, Inc.'s net income of $40.1M is higher than Akebia Therapeutics, Inc.'s net income of $540K. Notably, Ironwood Pharmaceuticals, Inc.'s price-to-earnings ratio is 26.41x while Akebia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ironwood Pharmaceuticals, Inc. is 2.03x versus 1.71x for Akebia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Outlook Therapeutics, Inc. has a net margin of 32.84% compared to Ironwood Pharmaceuticals, Inc.'s net margin of -1338.77%. Ironwood Pharmaceuticals, Inc.'s return on equity of -- beat Outlook Therapeutics, Inc.'s return on equity of --.

Ironwood Pharmaceuticals, Inc. has a consensus price target of $3.17, signalling downside risk potential of -22.39%. On the other hand Outlook Therapeutics, Inc. has an analysts' consensus of $6.83 which suggests that it could grow by 1058.19%. Given that Outlook Therapeutics, Inc. has higher upside potential than Ironwood Pharmaceuticals, Inc., analysts believe Outlook Therapeutics, Inc. is more attractive than Ironwood Pharmaceuticals, Inc..

Ironwood Pharmaceuticals, Inc. has a beta of 0.185, which suggesting that the stock is 81.483% less volatile than S&P 500. In comparison Outlook Therapeutics, Inc. has a beta of 0.174, suggesting its less volatile than the S&P 500 by 82.557%.

Ironwood Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Outlook Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ironwood Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Outlook Therapeutics, Inc. pays out -- of its earnings as a dividend.

Ironwood Pharmaceuticals, Inc. quarterly revenues are $122.1M, which are larger than Outlook Therapeutics, Inc. quarterly revenues of $1.5M. Ironwood Pharmaceuticals, Inc.'s net income of $40.1M is higher than Outlook Therapeutics, Inc.'s net income of -$20.2M. Notably, Ironwood Pharmaceuticals, Inc.'s price-to-earnings ratio is 26.41x while Outlook Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ironwood Pharmaceuticals, Inc. is 2.03x versus 11.36x for Outlook Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of 32.84% compared to Ironwood Pharmaceuticals, Inc.'s net margin of -316.61%. Ironwood Pharmaceuticals, Inc.'s return on equity of -- beat Plus Therapeutics, Inc.'s return on equity of --.

Ironwood Pharmaceuticals, Inc. has a consensus price target of $3.17, signalling downside risk potential of -22.39%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $7.16 which suggests that it could grow by 1077.61%. Given that Plus Therapeutics, Inc. has higher upside potential than Ironwood Pharmaceuticals, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Ironwood Pharmaceuticals, Inc..

Ironwood Pharmaceuticals, Inc. has a beta of 0.185, which suggesting that the stock is 81.483% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.845, suggesting its less volatile than the S&P 500 by 15.456%.

Ironwood Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ironwood Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Ironwood Pharmaceuticals, Inc. quarterly revenues are $122.1M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Ironwood Pharmaceuticals, Inc.'s net income of $40.1M is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Ironwood Pharmaceuticals, Inc.'s price-to-earnings ratio is 26.41x while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ironwood Pharmaceuticals, Inc. is 2.03x versus 9.74x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pyxis Oncology, Inc. has a net margin of 32.84% compared to Ironwood Pharmaceuticals, Inc.'s net margin of -650.85%. Ironwood Pharmaceuticals, Inc.'s return on equity of -- beat Pyxis Oncology, Inc.'s return on equity of -90.91%.

Ironwood Pharmaceuticals, Inc. has a consensus price target of $3.17, signalling downside risk potential of -22.39%. On the other hand Pyxis Oncology, Inc. has an analysts' consensus of $7.18 which suggests that it could grow by 405.28%. Given that Pyxis Oncology, Inc. has higher upside potential than Ironwood Pharmaceuticals, Inc., analysts believe Pyxis Oncology, Inc. is more attractive than Ironwood Pharmaceuticals, Inc..

Ironwood Pharmaceuticals, Inc. has a beta of 0.185, which suggesting that the stock is 81.483% less volatile than S&P 500. In comparison Pyxis Oncology, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ironwood Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pyxis Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ironwood Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pyxis Oncology, Inc. pays out -- of its earnings as a dividend.

Ironwood Pharmaceuticals, Inc. quarterly revenues are $122.1M, which are larger than Pyxis Oncology, Inc. quarterly revenues of --. Ironwood Pharmaceuticals, Inc.'s net income of $40.1M is higher than Pyxis Oncology, Inc.'s net income of -$22M. Notably, Ironwood Pharmaceuticals, Inc.'s price-to-earnings ratio is 26.41x while Pyxis Oncology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ironwood Pharmaceuticals, Inc. is 2.03x versus 30.86x for Pyxis Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.